Free tool
FAERS Monitor: Reyataz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206352 or its brand name (Reyataz, Atazanavir Sulfate). Reports on generic versions are filed under their own applications.
Reports
11,467
Serious
10,029
87% of reports
Hospitalization
3,551
Death reported
780
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction931
- anxiety759
- pain740
- foetal exposure during pregnancy718
- emotional distress651
- depression620
- anhedonia592
- renal failure453
- nephrolithiasis441
- nausea424
- fatigue395
- chronic kidney disease394
- osteoporosis394
- hyperbilirubinaemia346
- jaundice340
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 345 |
| 2005 | 459 |
| 2006 | 496 |
| 2007 | 362 |
| 2008 | 395 |
| 2009 | 598 |
| 2010 | 689 |
| 2011 | 769 |
| 2012 | 892 |
| 2013 | 623 |
| 2014 | 720 |
| 2015 | 808 |
| 2016 | 715 |
| 2017 | 553 |
| 2018 | 545 |
| 2019 | 608 |
| 2020 | 605 |
| 2021 | 499 |
| 2022 | 387 |
| 2023 | 207 |
| 2024 | 88 |
| 2025 | 66 |
| 2026 | 36 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,692 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperbilirubinaemiaSignal | 346 | 63.4 | 57.0 | 20,475 |
| anhedoniaSignal | 592 | 42.2 | 39.0 | 23,292 |
| jaundiceSignal | 340 | 23.5 | 21.1 | 7,208 |
| nephrolithiasisSignal | 441 | 17.8 | 16.2 | 6,923 |
| osteoporosisSignal | 394 | 17.7 | 16.1 | 6,156 |
| foetal exposure during pregnancySignal | 718 | 16.3 | 15.2 | 10,271 |
| drug interactionSignal | 931 | 10.8 | 10.2 | 8,303 |
| emotional distressSignal | 651 | 9.9 | 9.2 | 5,209 |
| chronic kidney diseaseSignal | 394 | 9.6 | 8.7 | 3,005 |
| renal failureSignal | 453 | 6.3 | 5.7 | 2,009 |
| depressionSignal | 620 | 5.0 | 4.6 | 2,002 |
| anxietySignal | 759 | 4.9 | 4.6 | 2,380 |
| painSignal | 740 | 2.2 | 2.1 | 504 |
| nausea | 424 | 1.0 | 0.9 | 0 |
| fatigue | 395 | 0.9 | 0.8 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.